PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

Eloso, Jessica; Awad, Asma; Zhao, Xinhua; Cunningham, Francesca; Zhang, Rongping; Dong, Diane; Kelley, Cathy; Glassman, Peter; Aspinall, Sherrie L.

doi:10.1016/j.ajmo.2023.100035

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is currently no standard definition of persistence. Different definitions to the one used in the present study have been reported in the literature, e.g., filled prescriptions [ 21 ], non-violation of certain gap windows [ 19 , 22 ], or self-reported surveys [ 20 , 23 ]. Additionally different periods of observation have been published [ 19 – 23 ].…”

Section: Discussionmentioning

confidence: 99%

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study

Lehrke,

Vogt,

Schettler

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Low-density lipoprotein cholesterol (LDL-C) is among the most important modifiable risk factors for cardiovascular disease. In very high-risk patients, the European Society of Cardiology/European Atherosclerosis Society guidelines recommend attaining LDL-C < 55 mg/dL. In the German cohort of the observational HEYMANS study, we aimed to describe the clinical characteristics and LDL-C control among patients initiating evolocumab. Methods Data was collected between 09/2016 and 05/2021 for ≤ 6 months before (retrospectively) and ≤ 30 months after evolocumab initiation (prospectively). Patient characteristics, lipid-lowering therapy (LLT), lipid values, evolocumab use, and safety were collected. Results Of 380 enrolled patients, 93% received evolocumab in secondary prevention and 69% had a history of statin intolerance. At study baseline, 49% did not receive any statins and LDL-C was very high (145 mg/dL). Use of evolocumab decreased LDL-C by a median of 53% within 3 months and remained stable thereafter, despite mainly unchanged background LLT. Overall, 59% attained an LDL-C level < 55 mg/dL (69% with, 49% without LLT). Persistence to evolocumab was 90.6% in months 1–12 and 93.5% in months 13–30. Adverse drug reactions were reported in 8% of patients. Conclusion Data from the German HEYMANS cohort corroborate previous reports on evolocumab effectiveness and safety in clinical practice. Evolocumab initiation was associated with a rapid and sustained LDL-C reduction. Persistence with evolocumab was high. Our finding that patients receiving an evolocumab/LLT combination are more likely to attain the LDL-C goal than those receiving evolocumab alone corroborates previous data showing the importance of using highly intensive therapy. Graphical abstract available for this article. Trial Registration ClinicalTrials.gov Identifier NCT02770131 (registration date 27 April 2016). Graphical Abstract Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02757-x.

show abstract